This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
The arithmetic in post #120 is right; the assumption feeding it is the part to check.
Trial adherence in an oral trial with strict administration requirements is genuinely worse than trial-published data often suggests. That is why the exposure variability in oral formulations is mentioned repeatedly in the discussions here.
Same conclusion as the reply above, reached differently, which is mildly reassuring.
What I would check first on Oral semaglutide bioavailability is whether the thing being measured moved or whether the way of measuring it moved. Those look identical in a graph.
Missed doses behave differently for a daily oral than for a weekly injection. With a short interval you are near a trough rather than perturbing a slowly moving average, and the labelling reflects that.
PIONEER 6 is the cardiovascular outcome trial for oral semaglutide and it enrolled a diabetes population at high cardiovascular risk. Quoting it outside that population is an extrapolation.
Adding the measurement that post #124 says would settle it.
Oral semaglutide's bioavailability is low and variable, which is why the dose numbers are an order of magnitude different from the injectable. That is a formulation consequence and not a difference in potency.
I have changed my mind on this once already, so take it as current rather than settled.
Post #122 describes the usual case. This is about the unusual one.
Oral versus injectable exposure: comparing a 14 mg oral dose with a 0.5 mg injectable dose is comparing apples to a different fruit. The oral bioavailability is low enough that dose numbers are an order of magnitude different and not directly comparable.
If it helps: the failure mode here is usually boring rather than dramatic.
The practical argument for an oral is adherence, and the published adherence data is less flattering than the argument. Daily dosing with fasting requirements is not obviously easier than a weekly injection.
I looked this up rather than remembered it, which is the right order.
Good question, well framed, and I would like to see it answered properly.
The SOUL trial: cardiovascular outcomes trial for oral semaglutide in people with type 2 diabetes and cardiovascular disease or chronic kidney disease. It demonstrates that benefit appears to be a property of the molecule and exposure, not specific to the route.
On post #127 — agreed on the reasoning, with one qualification.
Tablet integrity matters more than people expect for a formulation that depends on an absorption enhancer released at a particular place. Splitting or crushing is not a dose adjustment; it is a different product.
For what it is worth, the same held on the two occasions I checked.
Oral bioavailability is variable between people. Some people absorb well; others absorb poorly. That inter-individual variation is larger than with injectables and is one reason the trial data for oral formulations receives different treatment.
Adding it because I spent an afternoon working it out and nobody should have to twice.
Why administration conditions matter for oral semaglutide and not for injectables: the oral formulation depends on a transient pH effect in the stomach. Anything that changes gastric pH or transit time changes absorption. Food does both.
Dose equivalence between oral and injectable formulations is not a simple conversion and no published factor should be used as one. The two were developed and titrated separately.
Correct me on the arithmetic if it is wrong; I would rather know.
Since Oral semaglutide bioavailability keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience will review it.
Confirming post #137 from a second method, which matters more than confirming it from a second person.
The thirty-minute wait before eating is not conservatism. Food in the stomach materially reduces absorption of the oral product, and the instruction exists because the pharmacokinetic studies measured how much.
If anyone can point at the primary source I would be grateful.
The gastrointestinal tolerability profile of the oral formulation is broadly similar in character to the injectable, which supports the effects being systemic rather than local irritation.
The arithmetic in post #137 is right; the assumption feeding it is the part to check.
Why an oral formulation is a formulation achievement: the molecule is the same but the tablet is novel. Getting a peptide across the gastric epithelium at usable bioavailability is a chemistry problem, not a dose problem.
This follows post #138 rather than contradicting it.
A methods point on Oral semaglutide bioavailability rather than a substantive one: if the comparison is not like for like, the difference you are measuring is the difference in method.
On variability: the between-person spread in exposure for oral semaglutide is wide enough that two people on the same dose can have quite different plasma concentrations. That is inherent to the absorption route.
PIONEER programme is phase 3 for oral semaglutide. The trials cover multiple indications and durations. Reading them requires attention to which trial is which because they are not all the same question.
I would want a second opinion before relying on that.
Helpful, and easy to find again, which is half of what a good reply is.
Taking the oral product with more water than instructed reduces absorption rather than helping it. That is counter-intuitive and it is one of the few dosing instructions in this field with a clear pharmacokinetic basis.
Narrowing post #146, because the general version has more than one answer.
Trial adherence in an oral trial with strict administration requirements is genuinely worse than trial-published data often suggests. That is why the exposure variability in oral formulations is mentioned repeatedly in the discussions here.
Scoping that to what I have actually seen rather than what I have read.
Everything in post #145 holds. The case it does not cover is the one I have.
Oral bioavailability is variable between people. Some people absorb well; others absorb poorly. That inter-individual variation is larger than with injectables and is one reason the trial data for oral formulations receives different treatment.
Second-hand, so weight it accordingly.
Appreciated. The plain phrasing does more work here than a longer post would.